Introduction
The vascular endothelial growth factor (VEGF) is one of the most important initiators and regulators of angiogenesis and a key factor in cancer growth and progression (1) .
The VEGF gene is located on chromosome 6p12 and includes a 14-kb coding region, consisting of eight exons and exhibiting alternate splicing to form a family of proteins (2) . The gene is highly polymorphic, and several single nucleotide polymorphisms (SNPs) have been associated with altered gene expression and higher VEGF plasma levels (3-7). In addition, previous studies have revealed a correlation with cancer development and progression (8) (9) (10) (11) , as well as with Behcet's disease, adult respiratory distress syndrome, rheumatoid arthritis and psoriatic arthritis (12) (13) (14) (15) .
Colorectal cancer (CRC) is one of the most common malignancies in the world, with approximately 1 million new cases and half a million deaths worldwide in 2002 (16) . VEGF has also been demonstrated to be overexpressed in CRC tissue compared to normal colonic mucosa (17) (18) (19) (20) . Therefore, antiangiogenic therapy with VEGF inhibitors has attracted much attention as an additional treatment to standard therapeutic strategies for cancer. However, no predictive markers for high VEGF levels exist at present (21) .
In the present study, five polymorphisms of the VEGF gene and their possible association with VEGF mRNA levels, CRC development and various additional clinical/ pathological characteristics were investigated in Swedish CRC patients. Three of the polymorphisms are located in the promoter region at positions -2578, -2549 and -1154; one is in the 5'-untranslated region at position -634, and the fifth in the 3'-untranslated region at position +936 (7) .
In brief, VEGF mRNA was found to be overexpressed in CRC tissue compared to adjacent normal colonic mucosa, while no or only weak associations were evident between the SNPs examined in the VEGF gene, VEGF mRNA tumor levels and the risk of developing CRC. (22) .
Analysis of VEGF polymorphisms
RNA (200 ng) from each sample was reversely transcribed into cDNA with SuperScript™ III (Invitrogen) according to the supplier's recommendations. The relative gene expression of VEGF and of the internal control gene ß-glucuronidase (GUSB) was determined by real-time PCR (7500 Fast RealTime PCR System, Applied Biosystems, Foster City, CA, USA), performed with the TaqMan ® Fast Universal PCR Master Mix (Applied Biosystems) and predesigned primer/ probe mixes for VEGF (Hs00900054_m1, Applied Biosystems) and GUSB (4333767T, Applied Biosystems), respectively. Samples were run in duplicate, and the mean Ct values were translated into a relative concentration unit presented by the standard curve, which was co-amplified in each experiment. Finally, relative concentrations of VEGF were normalized to the expression of GUSB. VEGF levels in the tumor group and the normal colonic mucosa were compared, and their association with different VEGF genotypes and haplotypes was explored.
PCR amplification and genotyping assays. Primer sequences for the VEGF polymorphisms were designed based on the Genbank sequences M63971 and AF024710. The sequences, as well as more detailed PCR conditions, are available on request.
PCRs were carried out in a total reaction volume of 20 μl using 20 ng of genomic DNA with the following amplification protocol: 95˚C for 2.5 min followed by 35 cycles at 95˚C for 30 sec, 60˚C for 30 sec and 72˚C for 30 sec, with a final extension at 72˚C for 5 min.
-2549 del/ins 18 bp was genotyped by separation in a 3% NuSieve (Cambrex Bio Science Rockland Inc., Rockland, ME, USA)/1% agarose gel, and bands were visualized by ethidium bromide staining and UV-light.
The SNPs -2578 C/A (rs699947), -1154 G/A (rs1570360), -634 G/C (rs201963) and +936 C/T (rs3025039) were genotyped with the MegaBACE™ SNuPe™ Genotyping Kit (GE Healthcare, Buckinghamshire, UK) (primer sequences available on request) according to the manufacturer's recommendations.
Statistical analysis. The Hardy-Weinberg equilibrium of alleles was tested for each SNP to compare the observed genotype frequencies with the expected genotype frequencies among the control subjects.
Statistical analysis was performed with SPSS v15.0 (SPSS UK Ltd., Woking, UK) and EpiInfo v3.3.2 (Centers for Disease Control and Prevention, Atlanta, GA, USA). Odds ratios (OR) were calculated with corresponding Yates-corrected ¯2 tests and 95% confidence intervals (CI). P-values <0.05 (twotailed) were considered statistically significant.
Haplotype and linkage disequilibrium analysis was performed with Haploview v3.32 (http://www.broad.mit.edu/mpg/ haploview), where Lewontin's standardized disequilibrium coefficient D' was derived for each SNP and diplotypes were derived with Phase v2.1 (23) and analyzed using SPSS.
Power calculations were performed with PS v2.1.31 (24) and based on the comparison of the genotypes containing the assumed risk allele hypothesized to contribute to higher levels of VEGF (Table I ) and the genotype containing the assumed non-risk allele. An exception was VEGF +936 C/T, in which the TT genotype was found to be rare and combined with the heterozygous group. +936 C/T was also excluded from the haplotype analysis due to its weak association with the promoter/5'-UTR SNPs and the relatively low frequency of the T allele.
Relative mRNA concentrations were expressed as the means ± standard error (SE). The student's t-test was used to compare the mean values of the different groups.
Results
VEGF mRNA expression. VEGF-A mRNA expression levels were upregulated 2.1-fold in colorectal tumors compared to normal colonic mucosa (p<0.01) and slightly elevated in tumors with the C-G-G haplotype (-2578 C/A, -1154 G/A and -634 G/C, respectively) compared to levels in individuals not harboring this haplotype, although this difference did not reach statistical significance (1.7-fold upregulation) (p=0.09). No association regarding any of the other genotypes or haplotypes and VEGF-A mRNA levels was evident (data not shown), and no association was observed between VEGF mRNA levels and clinicopathological characteristics (data not shown).
Haplotype analysis and genotype/haplotype frequencies among patients and controls. Lewontin's standardized disequilibrium coefficient (D') was calculated as a measure for linkage disequilibrium (LD) between the studied SNPs in the VEGF gene (Fig. 1) . Promoter and 5'-UTR polymorphisms (-2578 C/A, -2549 del/ins 18 bp, -1154 G/A and -634 G/C) were found to be in tight or even complete LD (Fig. 1 ). -2578 C/A was therefore used as a marker in the haplotype analysis. On the other hand, the +936 C/T polymorphism was only weakly associated with the others, which is consistent with previous reports (6, 8) . Hence, it was excluded from further haplotype analysis.
The four most common haplotypes with frequencies >1% were C-G-C, A-A-G, C-G-G and A-G-G (-2578 C/A, -2549 del/ins and -1154 G/A, respectively). Haplotype frequencies are presented in Table I . No significant differences were observed when VEGF genotypes or haplotypes in the CRC cases and controls were compared (Table I) , nor were any associations between the genotypes or haplotypes and the various clinical/pathological data studied disclosed (data not shown).
However, combining the -2578 C and +936 T alleles revealed a small yet significant overrepresentation of this genotype combination in the CRC population (OR=1.6; 95% CI, 1.3-1.6; p=0.01).
In general, the allele and genotype distributions of the polymorphisms were in close agreement with previously published studies involving healthy Caucasians (6, 8) .
Statistical power. The study had a statistical power of ≥81% to detect an OR ≥1.9 regarding all genotypes/ haplotypes on a two-sided significance level of ·=0.05 (data not shown).
Discussion
VEGF is a major regulator of angiogenesis and a highly polymorphic gene with several genotypes shown to alter gene expression. In previous studies, the -2578 CC, -2549 del/del, -1154 GG and -634 CC genotypes were often correlated with increased VEGF production (3,5,7), while the +936 T allele was associated with lower VEGF plasma levels (4). However, reports in the literature are not in full agreement. Stevens et al (7) showed that several haplotypes containing the -634 C allele were associated with suppressed promoter activity in tumor cells.
VEGF plays a significant role in CRC progression (17) (18) (19) , but the potential role of these SNPs in VEGF tumor expression and their importance in tumor growth, as well as their characteristics, have yet to be fully elucidated.
In the present study, VEGF mRNA was found to be upregulated in colorectal tumors compared to normal colonic mucosa (2.1-fold, p<0.01), in agreement with previous studies (20, 25) . However, in the present samples, none of the polymorphisms/haplotypes investigated discriminated between high vs. low VEGF-expressing tumors, although there was a tendency toward enhanced VEGF mRNA levels (1.7-fold; p=0.09) among individuals harboring the C-G-G haplotype (-2578 C/A, -2549 del/ins and -1154 G/A) compared to those not harboring it. Previous studies investigating the relationship between VEGF SNPs and mRNA levels in CRC found no major associations (25, 26) , which is in line with our results and implies that the influence of VEGF promoter SNPs on VEGF expression may be limited in colorectal tumors. In contrast, other studies on plasma levels and cell cultures have been published (3, 4, 7) , revealing a strong influence of these polymorphisms on VEGF promoter activity and gene expression. Thus, the importance of these SNPs appears to differ depending on the tissue and cell type investigated. Possibly, upstream regulatory pathways such as HIF-1·, MAPK or PI3K (27, 28) , rather than variants in the regulatory regions of the VEGF gene, play a significant and more decisive role in regulating VEGF expression in colorectal cancer.
We also analyzed the correlation between the described VEGF polymorphisms (genotypes and combined haplotypes) and CRC susceptibility and clinicopathological characteristics in a sample population consisting of 302 CRC patients and 336 controls. A combination of the -2578 C and +936 T alleles was slightly more common in CRC patients compared to control individuals (OR=1.6; p=0.01), although the frequency of these combined alleles was relatively low (10.7 vs. 6.7% in the CRC and control group, respectively). Other studies, mostly involving a relatively small population sample, found different associations between the investigated SNPs and tumor development. Chae et al (29) found that the -634 G/ +936 T combination was associated with a decreased susceptibility to CRC in a Korean population, which in part contradicts our findings. We chose to combine +936 C/T with -2578 C/A rather than -634 G/C. However, the latter two are in strong LD and located in the same haplotype block, and should therefore not contribute significantly to the different results.
With regard to the +936 SNP, in a study by Chae et al the TT genotype was associated with a higher tumor grade, metastasis and increased levels of the CA19-9 tumor marker in serum. However, Hofmann et al (30) was not able to verify these results, and found no association between the -2578 C/A, -634 G/C and +936 C/T polymorphisms and CRC in an Austrian population, genetically more comparable to ours. A recent study by Maltese et al (31) showed a significant association between three VEGF promoter polymorphisms [rs699947 (-2578 C/A), rs833061 (-460 T/C) and rs2010963 (-634 G/C)] and the development of CRC in an Italian population. They found an association between VEGF -460 T/C polymorphisms and two haplotypes, C-C-C and A-C-G (-2578 C/A, -460 T/C and -634 G/C), related to this variant and the risk of developing CRC. In our study, we included the SNP rs1570360 but not rs833061, since these SNPs are in tight LD and located in the same haplotype block, which is also supported by similar genotype frequencies found in the two control populations. The reasons for differences depending on population in the results obtained are still obscure. However, excepting chance associations, hypothetical factors include different genetic backgrounds, diet/lifestyles, and/or spectra of colorectal tumors (e.g., localization and pathological phenotype).
Importantly, the power of our study to detect an OR ≥1.9 for any of the polymorphisms investigated in relation to CRC susceptibility was greater than 80%, indicating that Table I . Association of VEGF genotypes and haplotypes with colorectal cancer. 
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a The genotypes hypothesized to be the most probable risk factors for colorectal cancer.
b A-A-G is the haplotype hypothesized to have the lowest expression, and was used as the reference group. c Comparison between the haplotypes with a frequency >1% in the study population. Counts are based on the number of haplotypes.
d Data derived from Haploview and the Yates-corrected ¯2 test. Comparisons are between cases and controls for each haplotype. Counts are based on the number of haplotypes.
-----------------------------------------------------------------------------------------------------
the negative results obtained were probably not due to the relatively small size of the study population.
In conclusion, we demonstrated that VEGF mRNA is upregulated in colorectal tumors compared to normal colonic mucosa, but not significantly influenced by individual SNPs in the regulatory regions of the VEGF gene. A small but significant association between the combined -634 C and +936 T alleles and CRC susceptibility was observed, but no other association was found between the studied SNPs (genotypes or haplotypes) and CRC susceptibility or progression in our Swedish population sample. We therefore suggest that other mechanisms are responsible for individual differences in VEGF expression and its contribution to tumor development and progression.
